Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a global threat to human health has highlighted the need for the development of novel therapies targeting current and emerging coronaviruses with pandemic potential. The coronavirus main protease (Mpro, also called 3CLpro) is a validated drug target against coronaviruses and has been heavily studied since the emergence of SARS-CoV-2 in late 2019. Here, we report the biophysical and enzymatic characterization of native Mpro, then characterize the steady-state kinetics of several commonly used FRET substrates, fluorogenic substrates, and six of the 11 reported SARS-CoV-2 polyprotein cleavage sequences. We then assessed the suitability of these substrates for high-throughput screening. Guided by our assessment of these substrates, we developed an improved 5-carboxyfluorescein-based FRET substrate, which is better suited for high-throughput screening and is less susceptible to interference and false positives than existing substrates. This study provides a useful framework for the design of coronavirus Mpro enzyme assays to facilitate the discovery and development of therapies targeting Mpro.

Highlights

  • Coronaviruses are a family of viruses commonly found in wildlife, companion animals, livestock, and humans

  • Human coronaviruses include human coronavirus (HCoV)-229E, HCoV-OC43, HCoVNL63, and HCoV-HKU1 continuously circulating in the population and mostly cause mild symptoms associated with the common cold

  • The FRET substrates consist of a fluorophore and quencher pair separated by a SARS-CoV-2 polyprotein cleavage sequence

Read more

Summary

METHODS AND RESOURCES

Discovery of Mpro inhibitors has relied heavily on the use of high-throughput screens (HTS) using a FRET-based peptide substrate to monitor protease activity [5, 7, 12–17]. There have been inconsistent findings regarding the identification of potential Mpro inhibitors [20, 21, 23] This has highlighted a clear need for an improved SARS-CoV-2 Mpro assay that delivers better performance and improved consistency. We measured the kinetic efficiency of six SARS-CoV2 Mpro polyprotein cleavage sequences to determine the optimal substrate amino acid sequence. Guided by these results, an improved 5-carboxyfluorescein (FAM)-based FRET substrate was developed that is better suited for HTS and is less susceptible to interference and false positives than previously reported substrates. This study provides a useful framework for the design of assays aimed at discovering and developing new coronavirus Mpro inhibitors

Results
Discussion
Experimental procedures
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call